Wilson Therapeutics
44 articles about Wilson Therapeutics
-
Massachusetts in general and Boston, specifically Cambridge, is one of the two largest centers in the U.S. for biotech startups and life science companies (the other being the San Francisco Bay Area). Here’s a look at 13 Massachusetts life science companies that are showing both gains and losses—...
-
Abingworth Closes on $315 Million Fund Aimed at Life Science Companies in Europe and the U.S.
7/9/2018
Abingworth Bioventures closed out its latest investment fund aimed at supporting life science companies with $315 million. The latest fund, ABV VII, will be used to support investments in Europe and the United States. -
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
-
Alexion Offer for Wilson Therapeutics Accepted
5/25/2018
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its offer, through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been accepted by shareholders representing 97.7 percent of the total number of shares and votes in Wilson Therapeutics.
-
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
-
Alexion to Acquire Wilson Therapeutics
4/11/2018
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders.
-
Wilson Therapeutics Interim Report January 1-September 30, 2017
11/27/2017
Wilson Therapeutics Ready for Phase 3 July 1 - September 30, 2017.
-
Wilson Therapeutics' Nomination Committee Appointed
11/9/2017
The Nomination Committee has appointed Sarah Shackelton as its chairman.
-
Wilson Therapeutics Reaches Agreement With The FDA And EMA To Initiate Pivotal Phase 3 FOCuS study With WTX101 in Wilson Disease
10/24/2017
Wilson Therapeutics (publ) today announced that the discussions with the FDA and the EMA, regarding the study protocol for the single pivotal Phase 3 FOCuS trial for WTX101 in Wilson Disease, have been concluded successfully.
-
Wilson Therapeutics Release: Promising Preliminary Long-Term Data From WTX101 Phase II Extension Study To Be Presented At AASLD Annual Meeting
10/2/2017
-
Wilson Therapeutics Interim Report January 1 – June 30, 2017
8/24/2017
-
Wilson Therapeutics To Host Conference Call To Provide Second Quarter 2017 Business Update
8/17/2017
-
Wilson Therapeutics Strengthens Its Board Of Directors By The Appointments Of Birgitte Volck And Björn Odlander
5/22/2017
-
Wilson Therapeutics Interim Report January 1 - March 31, 2017
5/17/2017
-
Wilson Therapeutics Presents Promising Neurological Phase 2 Data For WTX101 At American Academy of Neurology Meeting
4/26/2017
-
Wilson Therapeutics Presented Positive Final Phase II Data For WTX101 At EASL Annual Meeting
4/24/2017
-
Wilson Therapeutics' 2016 Annual Report Published
4/19/2017
-
Notice Of Annual General Meeting In Wilson Therapeutics
4/18/2017
-
Wilson Therapeutics Interim Report January 1 – September 30, 2016
11/28/2016
-
Wilson Therapeutics Presents Updated Preliminary Clinical Data On WTX101 At The American Association for Study of Liver Diseases Liver Meeting
11/11/2016